Lyell Immunopharma, Inc.

LYEL · Nasdaq · SIC 2834: Pharmaceutical Preparations
89
SEC Filings

Business Summary

Lyell Immunopharma, Inc. is a late-stage clinical cell therapy company focused on developing T cell therapies for cancer. Its lead product candidates include rondecabtagene autoleucel (ronde-cel, LYL314) and LYL273 (formerly GCC19CART). The company conducts its own manufacturing at its LyFE Manufacturing Center in Bothell, Washington, and has no approved products or product revenue to date.

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLYELdiscussed_in_filing Cybersecurity
topic_mentionLYELdiscussed_in_filing Trusted Computing
topic_mentionLYELdiscussed_in_filing Blockchain & Crypto
topic_mentionLYELdiscussed_in_filing Capital Expenditure
topic_mentionLYELdiscussed_in_filing Regulation
topic_mentionLYELdiscussed_in_filing Healthcare & Bio
topic_mentionLYELdiscussed_in_filing Cybersecurity
topic_mentionLYELdiscussed_in_filing Trusted Computing
topic_mentionLYELdiscussed_in_filing Blockchain & Crypto
topic_mentionLYELdiscussed_in_filing Capital Expenditure
topic_mentionLYELdiscussed_in_filing Regulation
topic_mentionLYELdiscussed_in_filing Healthcare & Bio
topic_mentionLYELdiscussed_in_filing Cybersecurity
topic_mentionLYELdiscussed_in_filing Trusted Computing
topic_mentionLYELdiscussed_in_filing Blockchain & Crypto
topic_mentionLYELdiscussed_in_filing Capital Expenditure
topic_mentionLYELdiscussed_in_filing Regulation
topic_mentionLYELdiscussed_in_filing Healthcare & Bio
topic_mentionLYELdiscussed_in_filing Cybersecurity
topic_mentionLYELdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001628280-26-017253EDGAR94K words
2025-03-112024-12-310001628280-25-011978EDGAR—
2024-02-282023-12-310001628280-24-007592EDGAR—
2023-02-282022-12-310001628280-23-005572EDGAR—
2022-03-292021-12-310001628280-22-007708EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001628280-25-051619EDGAR62K words
2025-08-122025-06-300001806952-25-000008EDGAR—
2025-05-132025-03-310001628280-25-025135EDGAR—
2024-11-072024-09-300001628280-24-046285EDGAR—
2024-08-072024-06-300001628280-24-035617EDGAR—
2024-05-062024-03-310001628280-24-020467EDGAR—
2023-11-072023-09-300001628280-23-037360EDGAR—
2023-08-082023-06-300001628280-23-028215EDGAR—
2023-05-042023-03-310001628280-23-015765EDGAR—
2022-11-082022-09-300001628280-22-028929EDGAR—
2022-08-042022-06-300001628280-22-021109EDGAR—
2022-05-102022-03-310001628280-22-013611EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001628280-26-017244EDGAR4K words
2026-03-090001193125-26-097615EDGAR—
2025-12-080001193125-25-310469EDGAR—
2025-12-050001193125-25-309621EDGAR—
2025-11-120001628280-25-051603EDGAR—
2025-11-100001193125-25-273269EDGAR—
2025-11-030001193125-25-261753EDGAR—
2025-09-160001193125-25-205020EDGAR—
2025-08-120001806952-25-000007EDGAR—
2025-07-250001193125-25-164853EDGAR—

89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

cell-therapy oncology immuno-oncology regenerative-medicine-advanced-therapy-(rmat)-designation orphan-drug-designation fast-track-designation

Company Identity

CIK0001806952
TickerLYEL
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersBothell, Washington

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a99e5df908ed047cf1183c4312489f22843caf7bad5fa84c99310f74fd7c86bf
parent: a63f004e67a12b9e6ff2e326bf4fb7511ebc24434c79208003cc1cb034210821
content hash: a5c0e0264c3fde2c753f3d0791d626fe379616b3cd50dbd84e76c6269b54f022
signed: 2026-04-13T04:46:08.573Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf